Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies in Lung Cancer: Independent Conference Coverage of the World Conference on Lung Cancer 2020

Shirish M. Gadgeel, MD
Nicolas Girard, MD, PhD
Released: March 31, 2021
Back Next

References

  1. Yang H, Liang S, Schid R, et al. New horizons in KRAS-mutant lung cancer: dawn after darkness. Front Oncol. 2019;9:953.
  2. Hong D, Fakih, M, Strickler J, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207-1217.
  3. Li BT, Skoulidis F, Falchook G, et al. CodeBreaK 100: registrational phase 2 trial of sotorasib in KRAS p.G12C mutated non-small cell lung cancer. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract PS01.07.
  4. Jӓnne P, Papadopoulos K, Ou I, et al. A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRAS G12C inhibitor, in advanced solid tumors. Presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2019. Abstract CS5.
  5. Jӓnne PA, Rybkin II, Spira AI, et al. KRYSTAL-1: activity and safety of adagrasib (MRTX849) in advanced/metastatic non–small-cell lung cancer (NSCLC) harboring KRAS G12C mutation. Presented at: 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; October 24-25, 2020. Abstract LBA-03.
  6. Girard N, Bazhenova L, Minchom A, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract MA04.07.
  7. Sabari J, Shu C, Park K, et al. Amivantamab in post-platinum EGFR exon 20 insertion mutant non-small cell lung cancer. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract OA04.04.
  8. Riley GJ, Neal JW, Camidge DR, et al. Activity and safety of mobocertinib (TAK-778) in previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations from a phase 1/2 trial. Cancer Discov. 2021;[Epub ahead of print].
  9. Zhou C, Ramalingam S, Li B, et al. Mobocertinib in NSCLC with EGFR exon 20 insertions: results from EXCLAIM and platinum-pretreated patient populations. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract OA04.
  10. Smit EF, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01. J Clin Oncol. Presented at: 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020. Abstract 9504.
  11. Nakagawa K, Nagasaka M, Felip E, et al. Trastuzumab deruxtecan in HER2-overexpressing metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract OA04.05.
  12. Tsurutani J, Iwata H, Krop I, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. Cancer Discov. 2020;10:688-701.
  13. Spira A, Lisberg AE, Sands JM, et al. Datopotamab deruxtecan (Dat-DXd; DS-1062), a TROP-2 ADC, in patients with advanced NSCLC: updated results from TROPION-PanTumor01 phase 1 study. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract OA03.03.
  14. Li X, Xu Y, Gong F, et al. Interdependence of KRAS and TP53 mutations in predicting ICI efficacy in EGFR/ALKWT non-squamous NSCLC: results from 1129 patient-level data. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract OA07.06.
  15. Boyer M, Şendour MAN, Rodríguez-Abreu D, et al. Pembrolizumab plus ipilimumab vs pembrolizumab plus placebo as 1L therapy for metastatic NSCLC of PD-L1 TPS ≥ 50%: KEYNOTE-598. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract PS01.09.
  16. Brahmer JR, Rodriguez-Abreu D, Robinson AG, et al. KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumor proportion score (TPS) ≥ 50%. Ann Oncol. 2020;31(Suppl 4):LBA51.
  17. Ramalingam SS, Ciuleanu TE, Pluzanski A, et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: three-year update from CheckMate 227 Part 1. J Clin Oncol. Presented at: 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020. Abstract 9500.
  18. Reck M, Ciuleanu TE, Cobo Dols M, et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate9LA. Presented at: 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020. Abstract 9501.
  19. Lai GGY, Alvarez JJS, Yeo JC, et al. Randomized phase 2 study of nivolumab (N) versus nivolumab and ipilimumab (NI) combination in EGFR mutant NSCLC. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract OA01.06.
  20. Soo RA, Lim SM, Syn N, et al. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: current controversies and future directions. Lung Cancer. 2018;115:12-20.
  21. Kilickap S, Sezer A, Gümüş M, et al. EMPOWER-Lung 1: clinical benefits of first-line (1L) cemiplimab monotherapy by PD-L1 expression levels in patients with advanced NSCLC. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract OA01.03.
  22. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomized, controlled trial. Lancet. 2021;397:592-604.
  23. Nie W, Han B. Comutations in DDR pathways predict atezolizumab response in non-small cell lung cancer patients. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract OA07.03.
  24. Mazieres J, Rittmeyer A, Gadgeel S, et al. Atezolizumab vs docetazel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials. J Thorac Oncol. 2021;16:140-150.
  25. Wu Y-L, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small cell lung cancer. N Engl J Med. 2020;383:1711-1723.
  26. Wu Y-L, John T, Grohe C, et al. Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR mutated NSCLC. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract OA06.04.
  27. Majem M, Goldman JW, John T, et al. Patient-reported outcomes from ADAURA: osimertinib as adjuvant therapy in patients with resected EGFR mutated (EGFRm) NSCLC. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract OA06.03.
  28. Wu Y-L, Zhong W, Wang Q, et al. CTONG1104: adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial. Presented at: 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020a. Abstract 9005.
  29. Novello S. International tailored chemotherapy adjuvant (ITCA) phase III study of pharmacogenomic-driven versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small cell lung cancer. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract PS01.04.
  30. Kong F, Hu C, Matchtay M, et al. Results of RTOG 1106/ACRIN-6697: a randomized phase II trial of individualized adaptive radiotherapy using mid-treatment FDG-PET/CT and modern technology in locally advanced non-small cell lung cancer (NSCLC). Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract OA02.04.
  31. Paz-Ares LG, Spigel DR, Chen Y, et al. RESILIENT part 1: a phase II dose-exploration and dose-expansion study of second-line liposomal irinotecan monotherapy in adults with small cell lung cancer. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract FP10.04.
  32. Ponce-Aix S, Coté GM, Falcón A. Efficacy and safety profile of lurbinectedin-irinotecan in patients with relapsed SCLC: results from a phase Ib-II trial. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract OA11.04.
  33. Owonikoko T, Boyer M, Johnson M, et al. A phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune-oncology therapy against DLL3, in SCLC. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract OA11.03.
  34. Paterson AM, Brown KE, Keir ME, et al. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol. 2011;187:1097-1105.
  35. Yang J, Riella LV, Chock S, et al. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol. 2011;187:1113-1139.
  36. Fennel D, Ottensmeier C, Califano R, et al. Nivolumab versus placebo in relapsed malignant mesothelioma: preliminary results from the CONFIRM phase 3 trial. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract PS01.11.
  37. Popat S. A multicenter randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Presented at: 44th ESMO Congress; September 27 - October 1, 2019. Abstract LBA91.
  38. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicenter, randomized, open-label, phase 3 trial. Lancet. 2021;397:375-386.
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Bristol-Myers Squibb
Ipsen Biopharmaceuticals, Inc.
Janssen Pharmaceutica NV
Jazz Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings